C5 Acid Compounds Fortify Intestinal Mucosa Barrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current animal and human diets lack effective components to enhance intestinal mucosa barrier properties, leading to issues like leaky gut, decreased feed efficiency, and increased susceptibility to pathogens, with existing nutrients like glutamine showing limited efficacy and handling issues.
Innovation Solution
Incorporating C5 acid compounds, such as valeric acid, their salts, or esters, at concentrations of 0.025 wt.% or higher in animal feeds to strengthen tight junctions in the intestinal epithelial cells, thereby enhancing barrier properties and reducing pathogen colonization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glutamine is used to improve gut barrier properties, then barrier function may be enhanced, but efficacy is limited and handling/storage problems occur
Solution Approach 1:
The patent changes the chemical form of the supplement from amino acid (glutamine) to fatty acid derivative (valeric acid and its salts/esters), fundamentally altering the parameter of molecular structure. This transformation resolves the handling and storage issues while maintaining or improving gut barrier function, as the fatty acid derivatives are more stable and easier to store than amino acids.
Solution Approach 2:
The patent employs valeric acid and its derivatives as a temporary, easily administered supplement that can be incorporated into feed formulations. These compounds serve as a practical alternative to glutamine, providing the necessary barrier function enhancement without the storage and handling complexities, effectively acting as a disposable-friendly supplement.
2Reliability
If tight junctions are disrupted by pathogens, then barrier properties decrease leading to leaky gut, but preventing this requires effective barrier-strengthening components
Solution Approach 1:
The patent applies preliminary anti-action by incorporating valeric acid and its salts/esters into the feed before pathogen infection occurs. These compounds preemptively strengthen the tight junctions and intestinal barrier, creating a protective effect that prevents pathogen colonization and subsequent barrier disruption, rather than merely treating symptoms after infection occurs.
Solution Approach 2:
Valeric acid and its derivatives act as intermediary substances that mediate between the diet and the intestinal barrier. They serve as a bridge component that translates nutritional intake into enhanced barrier function, strengthening tight junctions and preventing pathogen penetration without directly attacking pathogens themselves.
3Reliability
If C5 acid compounds are added to animal feed at 0.025 wt.% or higher, then tight junctions are strengthened and barrier properties are enhanced, but this requires precise dosage control
Solution Approach 1:
The patent establishes a specific concentration parameter (0.025 wt.% or higher) for C5 acid compounds in the feed formulation. By defining this precise dosage range, the patent transforms the complex task of optimizing barrier function into a straightforward manufacturing specification, making it easier to control and reproduce the beneficial effects while maintaining tight junction strength.
Data Source
Figure 1~2
AI summary
The invention is directed to an animal feed or a human food product for improving barrier properties of the intestinal mucosa. In a first aspect, this object is met by providing an animal feed suitable for feeding mammals, birds and fish, or a food for human consumption comprising a C5 acid compound, wherein the dosage of said C5 acid compound in said animal feed is 0.025% or higher by weight, based on the total weight of said animal feed.